NCT01274897已完成3 期
A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea
Novartis Vaccines16 个研究点 分布在 2 个国家目标入组 450 人开始时间: 2010年12月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 450
- 试验地点
- 16
- 主要终点
- Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.
研究概览
简要总结
This study is designed to evaluate the immunogenicity and the safety of a quadrivalent vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 11 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals eligible for enrollment in this study were those:
- •who were 11-55 years of age inclusive and who, after the nature of the study had been explained:
- •had given written assent and/or for whom the parent/legal representative had provided written informed consent (11-19 years of age).
- •had provided written informed consent (20-55 years of age).
- •who the investigator believed that they or their parents/legal representatives would comply with the requirements of the protocol (e.g., completion of the Diary Card, return for follow-up visit).
- •who were in good health as determined by
- •medical history
- •physical assessment
- •clinical judgment of the investigator
- •who had negative urine pregnancy test for women of childbearing age.
排除标准
- •Individuals not eligible to be enrolled in the study were those:
- •who were unwilling or unable to give written informed assent or consent to participate in the study.
- •who were perceived to be unreliable or unavailable for the duration of the study period.
- •who were planning to leave the area of the study site before the end of the study period.
- •who had a previous or suspected disease caused by N. meningitidis.
- •who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment.
- •who had previously been immunized with a meningococcal vaccine.
- •who had received any investigational or non-registered product (drug or vaccine)within 28 days prior to enrollment or who expected to receive an investigational drug or vaccine prior to the completion of the study.
- •who had received any licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this study or who were planning to receive any vaccine within 30 days from the study vaccines. (Exception: Influenza vaccine was administered up to 15 days prior to study vaccination and at least 15 days after study vaccination)
- •who had experienced within the 7 days prior to enrollment significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥38°C) within 3 days prior to enrollment.
- •who had any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition).
- •who had epilepsy or any progressive neurological disease.
- •who had a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components, including latex allergies.
- •who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
- •received immunosuppressive therapy within 28 days prior to enrollment(any systemic corticosteroid administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 28 days prior to enrollment, or cancer chemotherapy)
- •received immunostimulants
- •received parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study
- •who were known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •who had any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
研究组 & 干预措施
MenACWY-CRM
Experimental
Subjects received one dose of MenACWY-CRM conjugate vaccine.
干预措施: Novartis MenACWY-CRM (Biological)
Placebo
Placebo Comparator
Subjects received the saline placebo.
干预措施: Saline Placebo (Biological)
结局指标
主要结局
Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.
时间窗: day 29
Immunogenicity was measured as the percentage of subjects with hSBA response and associated 95% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y by serum bactericidal assay using human complement, human serum bactericidal assay (hSBA), at day 29 (28 days after MenACWY-CRM vaccination). Seroresponse is defined as: 1. for subjects with a pre-vaccination hSBA titer \< 1:4, a postvaccination hSBA titer ≥ 1:8. 2. for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.
次要结局
- Number of Subjects Who Reported Local and Systemic Reactogenicity During 7 Days After MenACWY-CRM Vaccination(during 7 days of vaccination)
- Geometric Mean Titers (GMTs) of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.(day 1 and day 29)
- Percentages of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.(day 1 and day 29)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420
已完成
3 期
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of AgeInfluenza DiseaseNCT01346592Novartis Vaccines6,104
已完成
2 期
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsEbola Viral DiseaseNCT02416453Janssen Vaccines & Prevention B.V.423
已完成
3 期
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy ChildrenMeningococcal InfectionsNCT00616421Novartis Vaccines2,907
尚未招募
3 期
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)RabiesNCT05969626Ningbo Rongan Biological Pharmaceutical Co., Ltd.2,460